Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.


June Webinar

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Wednesday, 19 June 2024
11:00 am - 12:30 pm US Eastern / 5:00 pm - 6:30 pm Central Europe

**Live Japanese simultaneous translation will be available during the webinar and as a recording!**

Our live webinars are completely free of charge. Webinars are hosted on Zoom and audience members can ask questions using the Q&A feature. Real-time closed captioning is available for those with hearing impairments.

Sponsored by:



11:00 am – 11:05 am: Introduction and Welcome
IES President: Marc Rothenberg, MD, PhD
Moderators: Praveen Akuthota, MD & Matthieu Groh, MD, MSc

11:05 am – 11:25 am: Clinical Overview of EGPA
Praveen Akuthota, MD

11:25 am – 11:45 am: Clinical Manifestations of EGPA and the Impact of Eosinophil Depletion
Michael Wechsler, MD, MMSc

11:45 am – 12:05 pm: Multidisciplinary Approach and Future Directions in EGPA
David Jackson, FRCP, MSc, PhD

12:05 pm – 12:30 pm: Panel Discussion and Audience Q&A

Speakers & Moderators

Praveen Akuthota, MD

Dr. Akuthota’s research efforts range from basic scientific investigations of human eosinophil biology and eosinophilic inflammation to clinical and translational efforts in asthma and eosinophilic pulmonary disease. He is the PI for the San Diego Clinical Center in the NHLBI PrecISE Network that is studying precision interventions in severe asthma. His research group is involved in other multicenter studies in eosinophilic disease and asthma. He has written several reviews and chapters discussing eosinophil immunobiology and clinical considerations in eosinophilic diseases.

Michael Wechsler, MD, MMSc

Michael E. Wechsler is Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at NJH in Denver, Director of the National Jewish Health (NJH)/Cohen Family Asthma Institute and Associate Vice President for Innovation and Industry Relations at NJH. In addition to clinical work in pulmonary & critical care medicine, Professor Wechsler’s research focuses on clinical and translational asthma with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (i.e. Churg-Strauss Syndrome, CSS). He has led studies focusing on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab. He has published more than 250 peer-reviewed manuscripts relating to asthma, EGPA and eosinophilic lung diseases. He was a member of the Steering Committee and site Principal Investigator of the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multicentre asthma clinical trials consortium, and currently serves as the PI of the Denver site of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. A member of the American Society of Clinical Investigation and the Association of American Physicians, he has participated in many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society and the International Eosinophil Society. He is currently Associate Editor of the journal Chest and has served as Associate Editor of the journal Allergy and on the editorial board of the European Journal of Clinical Investigation.

Dr. Wechsler received AB and MMSc degrees from Harvard University in Boston and an MD degree from McGill University in Montreal. He completed medical training at Beth Israel Hospital in Boston, and as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.

David Jackson, FRCP, MSc, PhD

David Jackson is an Associate Professor in Respiratory Medicine at King’s College London and Head of Guy’s Severe Asthma Centre at Guy's and St Thomas' Hospitals in London. This is the main tertiary referral unit for severe asthma and eosinophilic lung diseases in the region with over 500 patients treated with biologic therapies for severe asthma and EGPA.

During his clinical training Dr Jackson gained an MSc in allergy and a PhD in the pathophysiology of asthma exacerbations from Imperial College. He is an Associate Editor at Allergy and European Respiratory Review, and the Reviews editor at Chest.  He has published widely in the field of type 2 immunity, biologic therapies in asthma, and the mechanisms of virus-induced asthma exacerbations.

Matthieu Groh, MD, MSc

Dr. Groh is a clinical immunologist at Foch hospital (Suresnes, France) and is also board-certified in infectious diseases. He is deputy head of the French Reference Center for Hypereosinophilic Syndromes (CEREO) and runs a Reference Center for IgG4-Related Disease. His research interests cover the full spectrum of eosinophilic disorders, including myeloid and lymphoid variants of HES, EGPA, IgG4-Related Disease and organ-restricted eosinophil-associated diseases. He is the lead author of the European Respiratory Society and European Federation of Internal Medicine-endorsed consensus task force recommendations for the management of EGPA as well as the French guidelines for the management of HES.

Dr. Groh also coordinates a Therapeutic Patient Education program dedicated to patients with eosinophilic disorders, and is co-investigator of several clinical trials evaluating the efficacy of biologics targeting type 2 inflammation in HES, EGPA and EoE.  


How to Activate Simultaneous Japanese Translation on Zoom:

Corporate Advisory Council
Platinum Member

Astra Zeneca

Gold Members

AllakosAmgenGSKSanofi Regeneron

Bronze Members

Areteia TherapeuticsBMSCelldexTakeda